months sales presentation Webcast for investors, analysts & media

Transcription

1 months sales presentation Webcast for investors, analysts & media Basel, 27 October Disclaimer This presentation contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. Straumann is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise. The availability and indications/claims of the products illustrated and mentioned in this presentation may vary according to country. 2

2 Highlights Marco Gadola, CEO Strong all-round performance continues in REVENUE GROWTH BUSINESSES STRONGEST REGIONS +12.5% in organic terms 1 Double-digit growth +14.4% in CHF continues across all businesses; Instradent posts triple-digit increase North America & APAC Entry into Argentina (2 nd largest market in LATAM) PRODUCT HIGHLIGHT STRATEGIC HIGHLIGHTS FULL-YEAR GUIDANCE Variobase abutment family Versatile, cost-effective solution; high double-digit growth since launch 3 years ago; sold Creating opportunities EMEA reorganization to free up resources for emerging markets; Instradent European hub operational; shared technology platform expanded On track to achieve low-double-digit organic revenue growth with further EBIT margin improvement (barring unforeseen circumstances) 4 1 Organic growth i.e. excluding the effects of currency fluctuations and acquired/divested business activities

3 A fourth consecutive quarter of double-digit growth Organic revenue growth in % North America 28% of Group EMEA 45% of Group APAC 17% of Group M 9M LATAM 10% of Group 14.5 Group 9M M 9M 5 Business and regional review Peter Hackel, CFO

4 Strong expansion across all regions Revenue development (in CHF million, rounded) 15.3% in CHF 13.2% organic 11% LATAM % APAC % North America Change in organic growth 0.9% 1.0% 9.5% 15.5% 19.4% 14.5% 34% EMEA Revenue 9M 2015 FX effect M&A effect Revenue 9M FX 2016 EMEA North America APAC LATAM Revenue 9M 2016 Contribution to growth 7 EMEA robust impressive performance in North America Revenue change (organic) EMEA 45% 8.3% Q2 8.5% 56% 11.1% 9.4% 8.3% 7.7% Q4 Q Q2 Robust ; results generally positive Iberia, Italy and France among the principal contributors Zinedent joint-venture in Turkey adds to growth North America 28% 9.3% Q2 6.1% 6.6% Q4 16.9% 17.3% 12.5% Q Q2 Strong performance; +17% in Healthy growth in all business segments BLT helps win new general dentists and surgeons (40% of Straumann implants sold in region are BLT) Instradent reports notable gains 8

5 APAC & LATAM keep the pace up Revenue change (organic) Asia Pacific 17% 12.8% 13.2% Q2 20.0% 21.0% 20.2% 17.0% Q4 56% Q Q2 Growth in exceeds market growth Key performer: China Chinese value segment entered - first full quarter of sales from Anthogyr LATAM 10% 15.6% Q2 1.3% 16.8% 13.3% Q4 Q % 12.7% Q2 revenue up 13% from comparatively low baseline Strong performances in Mexico and Brazil (despite stagnant market) Strong demand for BLT LATAM overtakes other regions in less than a year 9 Double-digit growth in all businesses Implants Restorative Biomaterials 10

6 Update on strategic progress Marco Gadola, CEO Update on our strategic priorities Drive a high performance culture and organization Target unexploited growth markets & segments Become THE Total Solution Provider for Tooth Replacement 12

7 Entry into LATAM s 2nd largest market Argentina Subsidiary in Buenos Aires goes into operation and will address premium and non-premium segments Distributor business taken over Direct access to Argentinian market through own marketing, sales force, education, etc. 2 nd largest market in Latin America with ~400k implants placed in 2015: 97 per 10k population 1 ) 13 1 Straumann estimates Instradent Europe now operational value offering and competitive position strengthened European hub in Freiburg, Germany, to serve countries without Instradent organizations and to accelerate market penetration Hub provides warehouse, distribution & supply, customer services, as well as commercial management for customers, distributors and agents New markets served directly by hub Markets with established Instradent subsidiaries 14

8 Rapidly expanding footprint in the non-premium segment Neodent home market Medentika home market Equinox home market Instradent/Manohay footprint Instradent/Neodent distributors 15 Re-allocation in Europe to free up resources for emerging markets (effective ) Jens Dexheimer EVP Europe Wolfgang Becker EVP Distributor & Emerging Markets EMEA Europe Subsidiaries reallocated Distributor/emerging markets 16

9 Production expansion to meet growing demand Premium segment Villeret (CH) & Andover (US) to increase output by a quarter in 2016/17 through capacity optimization and investments in plant & equipment Value segment Curitiba (BR) will almost double capacity in coming years 17 Update on our strategic priorities Drive a high performance culture and organization Target unexploited growth markets & segments Become THE total solution provider for tooth replacement 18

10 Steps initiated to become a Total Solution Provider Diagnosis & treatment planning Implant Tooth replacement Regenerative Bone augmentation Membrane Soft tissue repair Prosthetics Standard & customized Accelerated treatment protocols Implant maintenance Wound healing Enhanced bone regeneration Geographical reach 3 rd party prosthetics Restoration materials Digital Dentistry Fully integrated digital treatment workflow Today Expansion areas 19 Technology & manufacturing platform: update and further expansion Germany (100%) Canada (55%) Brazil (100%) Germany (51%) Spain (30%) USA (13%) France (30%) Turkey (50%) (joint venture) Germany Switzerland (44%) S. Korea (arbitration) Taiwan (49%) Premium Austria Canada (30%) Common technology and manufacturing platform Taiwan (conv. bond) Value India (100%) (coming months) 20 Implants CADCAM/prosthetics Regeneratives

11 Straumann invests in V2R Biomedical specialist in guided-surgery planning Canadian company specialized in guided-surgery planning since % stake acquired with option to increase to full ownership Smile-in-a-box concept to provide drill guide plus all components together for single/multiple/full-arch replacements in a single surgical appointment Data acquisition Planning & design Production Smile in a box Surgery 21 Straumann launches Novaloc attachment system for implant-borne removable dentures Innovative, amorphous, diamond-like, carbon coating (ADLC) for durability Removable, variable matrix inserts (low maintenance) Precise alignment & seating; original Straumann connection Successful launches in Europe & Australia; other markets to follow Developed by Swiss technology partner Valoc Preferred alternative to previous system 22

12 New chairside system enters controlled market release Straumann Amann Girrbach chairside mill Market acceptance tests underway in Central Europe Straumann/Dental Wings intra-oral scanner Attractively priced; launched in US (Benco and Burkhart) Pilot in Germany; further test markets in Europe to follow with rollouts planned in Reach broadened to become a total solution provider Centralised milling Intra-oral scanning In-lab milling / practice lab Lab scanning or 3 rd party scanners Chairside milling Scan of patient case Prosthetic design Manufacturing 24

13 Planmeca adds distribution power for Straumann s n!ce material Unique glass ceramic for single-tooth restoration, optimized for chairside ( mill-polish-seat concept; no crystallization firing required 1 ) Commercialization through all Straumann Group channels underway Global distribution rights granted to Planmeca Oy to add marketing power and to help build the brand worldwide, Planmeca is a well-established leader in high-tech dental markets worldwide; range includes dental equipment, software and CADCAM solutions 25 1 Crystallization process typically takes minutes, depending on material and oven equipment Cooperation with Zirkonzahn SARL opens door to new group of lab customers Zirkonzahn to distribute Straumann Variobase abutments International supplier of lab solutions, including prosthetics for a wide range of implant systems Customers using Zirkonzahn s digital workflow gain easy access to Straumann cost-effective abutments with original connections Test-market roll-out under way in Germany 26 Zirkonzahn is a registered brand name of the respective company.

14 Outlook 2016 Guidance 2016 reiterated Barring unforeseen circumstances Straumann expects the global implant market to grow solidly in 2016 and is confident that it can continue to outperform Aims to achieve full-year organic growth in the low-double-digit range Despite further investments in strategic growth initiatives, the expected revenue growth and operational leverage should lead to further improvements in the underlying full-year EBIT margin (2015: 23%). 28

15 Questions & answers Calendar of upcoming events October revenue publication Webcast 02 November Vontobel Healthcare Tour Basel 15 November Investor meetings Zurich 17 November Credit Suisse Mid Cap Conference Zurich 08 December Credit Suisse European Healthcare Trip HQ, Basel January Bellevue Meets Management Seminar Zurich 16 February Full-year results conference HQ, Basel 07 April AGM 2016 Messe Basel Social media Analyst Talk Executive interviews Straumann.com / youtube.com StraumannIR Investor Relations 30 More information on straumann.com Events

16 Straumann s currency exposure BRL 10% Revenue breakdown FY Other 19% CHF 9% EUR 33% FX sensitivity Average exchange rates (rounded) (+/- 10%) on full-year M 2016 Revenue EBIT 1 EURCHF /- 26m +/- 16m 1 USDCHF /- 20m +/- 7m 1 BRLCHF /- 8m +/- 2m 100 JPYCHF /- 5m +/- 3m USD/CAD /AUD 29% Cost breakdown FY BRL 11% Other 11% CHF 37% USD/CAD /AUD 24% EUR 19% EURCHF BRLCHF USDCHF JPYCHF 31 1 These distribution charts represent the total net revenues and the total COGS, as well as OPEX in the various currencies. All numbers are rounded and based on FY 2015 figures and include Neodent since 1 March Your contacts Corporate Investor Relations Fabian Hildbrand Tel. +41 (0) investor.relations@straumann.com Corporate Communications Mark Hill Thomas Konrad Tel. +41 (0) Tel. +41 (0) mark.hill@straumann.com thomas.konrad@straumann.com 32